Freeline Therapeutics Holdings $158.8 million IPO
Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Kinsale Capital Group $59 million follow-on offering
Davis Polk advised the sole book-running manager and representative of the underwriters in connection with the $59 million follow-on offering of 310,500 shares of common stock of Kinsale…
Freeport-McMoRan $1.5 billion notes offering
Davis Polk advised Freeport-McMoRan Inc. (“FCX”) in connection with its SEC-registered offering of $1.5 billion of senior notes. The offering consisted of $650 million of 4.375% senior…
Trean Insurance Group $160 million IPO
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $160 million initial public offering of 10,714,286 shares of common…
BRP Group $175.2 million follow-on offering
Davis Polk advised BRP Group, Inc. on its $175.2 million follow-on offering of 13,225,000 shares of Class A common stock, which includes 1,725,000 shares from the full exercise of the…
Editas Medicine $215.6 million stock offering
Davis Polk advised the sole book-running manager in connection with the $215.6 million common stock offering of 6,900,000 shares of common stock of Editas Medicine, Inc. The common…
SoftBank $20 billion monetization of its T-Mobile shareholdings
As part of the transaction, T-Mobile used proceeds from a new $16 billion stock offering to purchase its shares from SoftBank
Viasat $400 million senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Viasat, Inc. of $400 million aggregate principal amount of its 6.500%…
IVERIC bio $160 million stock and warrants offering and private placement
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $124.7 million SEC-registered offering of 28,503,220 shares of…
Constellation Pharmaceuticals $192.5 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $192.5 million offering of common stock of Constellation…